Biotech News

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Ascendis Pharma (ASND)Ascendis Pharma2026-10-16 12:29 ESTCompany update

Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

ASNDAscendis Pharma2026-10-16 12:29 EST

Stock data

Close: 242.99 USD
Market cap: 13.38B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Related news

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

Ascendis Pharma

Recent company news

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

Ascendis Announces Planned $400 Million Share Repurchase Program

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

Ascendis Announces Planned $400 Million Share Repurchase Program

Stock data